{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:29:33Z","timestamp":1778509773713,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.antiviral.2018.01.009","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T15:26:28Z","timestamp":1517412388000},"page":"71-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Synergy evaluation of anti-Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0185-3147","authenticated-orcid":false,"given":"Elena","family":"Criscuolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicasio","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Burioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Miduri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.01.009_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","author":"Bliss","year":"1939","journal-title":"Ann. Appl. Biol."},{"key":"10.1016\/j.antiviral.2018.01.009_bib2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nrmicro974","article-title":"Passive antibody therapy for infectious diseases","volume":"2","author":"Casadevall","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2018.01.009_bib3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2018.01.009_bib4","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1080\/10428190802353591","article-title":"Preclinical versus clinical drug combination studies","volume":"49","author":"Chou","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.antiviral.2018.01.009_bib5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.antiviral.2018.01.009_bib6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.antiviral.2018.01.009_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.antiviral.2018.01.009_bib8","first-page":"1","article-title":"Role and potential therapeutic use of antibodies against herpetic infections","author":"Clementi","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.antiviral.2018.01.009_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2017.03.028","article-title":"Entry inhibition of HSV-1 and -2 protects mice from viral lethal challenge","author":"Clementi","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.01.009_bib10","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.drudis.2012.11.006","article-title":"Characterization of epitopes recognized by monoclonal antibodies: experimental approaches supported by freely accessible bioinformatic tools","volume":"18","author":"Clementi","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.antiviral.2018.01.009_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/3780697","article-title":"Bacteriophages and their immunological applications against infectious threats","volume":"2017","author":"Criscuolo","year":"2017","journal-title":"J. Immune Res."},{"key":"10.1016\/j.antiviral.2018.01.009_bib12","article-title":"Novel combination of salinomycin and resveratrol synergistically enhances the anti-proliferative and pro-apoptotic effects on human breast cancer cells","volume":"0","author":"Dewangan","year":"2017","journal-title":"Apoptosis"},{"key":"10.1016\/j.antiviral.2018.01.009_bib13","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.antiviral.2018.01.009_bib14","series-title":"Enhanced Anticancer Activity of PF-04691502, a Dual PI3K\/mTOR Inhibitor, in Combination with VEGF siRNA against Non-small-cell Lung Cancer","first-page":"1","author":"Espana-Serrano","year":"2016"},{"key":"10.1016\/j.antiviral.2018.01.009_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.antiviral.2018.01.009_bib16","article-title":"Versuche \u00fcber kombination von desinfektionsmitteln","author":"Frei","year":"1913","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2018.01.009_bib17","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.tiv.2007.03.003","article-title":"A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model","volume":"21","author":"Goldoni","year":"2007","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.antiviral.2018.01.009_bib18","article-title":"Consensus on concepts and terminology for combined-action assessment: the Saariselk\u00e4 agreement","author":"Greco","year":"1992","journal-title":"Arch Complex Environ. Stud."},{"key":"10.1016\/j.antiviral.2018.01.009_bib19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","author":"Greco","year":"1995","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.antiviral.2018.01.009_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/S0031-6997(25)06847-4","article-title":"The search for synergy: a critical review from a response surface perspective","author":"Greco","year":"1995","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.antiviral.2018.01.009_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.virol.2012.09.017","article-title":"Tools from viruses: bacteriophage successes and beyond","volume":"434","author":"Henry","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.01.009_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.clp.2014.10.005","article-title":"Neonatal herpes simplex virus infection: epidemiology and treatment","volume":"42","author":"James","year":"2015","journal-title":"Clin. Perinatol."},{"key":"10.1016\/j.antiviral.2018.01.009_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3892\/ijo.2013.1930","article-title":"Analyses of the combination of 6-MP and dasatinib in cell culture","volume":"43","author":"Kaur","year":"2013","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.antiviral.2018.01.009_bib24","article-title":"Genistein synergizes centchroman action in human breast cancer cells","volume":"48","author":"Kaushik","year":"2016","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.01.009_bib25","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1128\/AAC.46.3.762-768.2002","article-title":"Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines","volume":"46","author":"Leary","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.01.009_bib26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/ilar.46.3.258","article-title":"Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources","volume":"46","author":"Lipman","year":"2005","journal-title":"ILAR J."},{"key":"10.1016\/j.antiviral.2018.01.009_bib27","first-page":"285","article-title":"The problem of synergism and antagonism of combined drugs","volume":"3","author":"Loewe","year":"1953","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.antiviral.2018.01.009_bib28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF01952257","article-title":"Effect of combinations : mathematical basis of problem","volume":"114","author":"Loewe","year":"1926","journal-title":"Arch. Exp. Pathol. Pharmakol."},{"key":"10.1016\/j.antiviral.2018.01.009_bib29","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.1311846111","article-title":"High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells","volume":"111","author":"Mathews Griner","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.antiviral.2018.01.009_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2018.01.009_bib31","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1128\/JVI.01986-07","article-title":"Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein","volume":"82","author":"Perotti","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.01.009_bib32","series-title":"Handbook of Antimicrobial Resistance","article-title":"Antiviral drug resistance in herpesviruses","author":"Piret","year":"2017"},{"key":"10.1016\/j.antiviral.2018.01.009_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints 1 2","author":"Reed","year":"1938","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.antiviral.2018.01.009_bib34","first-page":"421","article-title":"Synergism of alkaline extract of the leaves of sasa senanensis rehder and antiviral agents","volume":"30","author":"Sakagami","year":"2016","journal-title":"In Vivo"},{"key":"10.1016\/j.antiviral.2018.01.009_bib35","first-page":"289","article-title":"A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments","volume":"35","author":"Solforosi","year":"2012","journal-title":"N. Microbiol."},{"key":"10.1016\/j.antiviral.2018.01.009_bib36","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nbt.2391","article-title":"Systematic identification of synergistic drug pairs targeting HIV","volume":"30","author":"Tan","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2018.01.009_bib37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fphar.2015.00181","article-title":"What is synergy? The Saariselk\u00e4 agreement revisited","volume":"6","author":"Tang","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.01.009_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF00136456","article-title":"Analysis of HSV isolated from patients with unilateral and bilateral herpetic keratitis","volume":"8","author":"Tognon","year":"1985","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.antiviral.2018.01.009_bib39","doi-asserted-by":"crossref","unstructured":"Webb, J.L., 1963. Effect of more than one inhibitor. Enzyme and metabolic inhibitors.","DOI":"10.5962\/bhl.title.7320"},{"key":"10.1016\/j.antiviral.2018.01.009_bib40","first-page":"97","article-title":"Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method","volume":"6","author":"Zhang","year":"2016","journal-title":"Am. J. Cancer. Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217307696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217307696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T10:06:35Z","timestamp":1751277995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354217307696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":40,"alternative-id":["S0166354217307696"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.01.009","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergy evaluation of anti-Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}